Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (廣州銀諾醫藥集團股份有限公司) (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Upon completion of the issuance and listing of the H shares on the Main Board of the Stock Exchange on 15 August 2025 (the "**Listing**"), the Company is required to make amendments to its articles of association (the "**Articles of Association**") and complete the filing of the relevant amendments to the Articles of Association to reflect the changes in its registered capital, total number of shares and other related matters after the Listing.

Pursuant to the resolutions passed at the extraordinary general meeting of the Company on 30 October 2024, the Board and persons authorised by the Board have been authorised to make corresponding adjustments and amendments to the Articles of Association in accordance with the advice of the relevant domestic and overseas regulatory authorities, and taking into account the actual circumstances of the Company.

In view of the above, the following amendments were made to the Articles of Association:

Article No.	Existing Articles of Association	Amended Articles of Association
Article 3	The Company made an initial offering of [•] ordinary shares of overseas-listed foreign shares (H shares), with a nominal value of RMB1.00 per share, to investors upon approval by The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") on [•] and upon filing with the China Securities Regulatory Commission (the "CSRC") on May 29, 2025 and was listed on the Main Board of the Hong Kong Stock Exchange on [•].	The Company made an initial offering of ~~[•]~~36,556,400 ordinary shares of overseas-listed foreign shares (H shares), with a nominal value of RMB1.00 per share, to investors upon approval by The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") on ~~[•]~~August 5, 2025 and upon filing with the China Securities Regulatory Commission (the "CSRC") on May 29, 2025 and was listed on the Main Board of the Hong Kong Stock Exchange on ~~[•]~~August 15, 2025. ......

Article No.	Existing Articles of Association	Amended Articles of Association
Article 6	The Company's registered capital: RMB[•].	The Company's registered capital: RMB~~[•]~~456,819,349.
Article 14	Upon registration in accordance with the law, the Company's business scope includes: Pharmaceutical research and development (R&D); Manufacturing of pharmaceutical products; Contract manufacturing of pharmaceutical products; Sale of pharmaceutical products; Consignment sale of pharmaceutical products; Medical research and experimental development; Technical services, technology development, technical consulting, technology exchange, technology transfer, and technology promotion; Production of Class I medical devices; Production of Class II medical devices; Production of Class III medical devices; Retail of pharmaceutical products; Wholesale of pharmaceutical products; Import and export of pharmaceutical products; Pharmaceutical Internet information services. The business scope referred to in the preceding paragraph shall be such items as approved by the company registration authority.	Upon registration in accordance with the law, the Company's business scope includes: ~~Pharmaceutical research and development (R&D); Manufacturing of pharmaceutical products; Contract manufacturing of pharmaceutical products; Sale of pharmaceutical products; Consignment sale of pharmaceutical products;~~ Medical research and experimental development; Technical services, technology development, technical consulting, technology exchange, technology transfer, and technology promotion; Production of Class I medical devices; Manufacturing of pharmaceutical products; Production of Class II medical devices; Production of Class III medical devices.~~; Retail of pharmaceutical products; Wholesale of pharmaceutical products; Import and export of pharmaceutical products; Pharmaceutical Internet information services.~~ The business scope referred to in the preceding paragraph shall be such items as approved by the company registration authority.

Article No.	Existing Articles of Association	Amended Articles of Association
Article 20	The Company may issue no more than [•] overseas-listed foreign shares to investors and convert [•] domestic shares issued by the Company into overseas-listed foreign shares upon filing with the CSRC and approval by the Hong Kong Stock Exchange. Upon completion of the aforementioned issuance of overseas-listed foreign shares (assuming the over-allotment option is not exercised) and the conversion of domestic unlisted shares into overseas-listed shares, the Company's share capital structure will be: [•] ordinary shares, comprising [•] domestic unlisted shares and [•] overseas-listed shares. Upon completion of the aforementioned issuance of overseas-listed foreign shares (assuming the over-allotment option is exercised in full) and the conversion of domestic unlisted shares into overseas-listed shares, the Company's share capital structure will be: [•] ordinary shares, comprising [•] domestic unlisted shares and [•] overseas-listed shares.	The Company may issue no more than ~~[•]~~69,043,500 overseas-listed foreign shares to investors and convert ~~[•]~~383,728,970 domestic shares issued by the Company into overseas-listed foreign shares upon filing with the CSRC and approval by the Hong Kong Stock Exchange. Upon completion of the aforementioned issuance of overseas-listed foreign shares ~~(assuming the over-allotment option is not exercised)~~ and the conversion of domestic unlisted shares into overseas-listed shares, ~~the Company's share capital structure will be: [•] ordinary shares, comprising [•] domestic unlisted shares and [•] overseas-listed shares. Upon completion of the aforementioned issuance of overseas-listed foreign shares (assuming the over-allotment option is exercised in full) and the conversion of domestic unlisted shares into overseas-listed shares,~~ the Company's share capital structure will be: ~~[•]~~456,819,349 ordinary shares, comprising ~~[•]~~36,533,979 domestic unlisted shares and ~~[•]~~420,285,370 overseas-listed shares.

Save for the amendments disclosed above, other provisions of the Articles of Association remain unchanged. The amendments to the Articles of Association are prepared in Chinese and the English translation is for reference only. In case there are any inconsistencies between the Chinese version and the English version, the Chinese version shall prevail.

The full text of the amended Articles of Association is available on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.innogenpharm.com).

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the PRC, 17 December 2025

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.